12:00 , May 20, 2019 |  BioCentury  |  Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

With a $50 million series A led by NEA and a management team guided by veterans of Shire takeout Lumena, Reneo believes its small molecule could carve out a niche in the rare genetic mitochondrial...
19:15 , Jun 22, 2018 |  BC Week In Review  |  Company News

UCSD launches bacteriophage treatment center

The University of California San Diego launched the Center for Innovative Phage Applications and Therapeutics (IPATH) to develop bacteriophages to fight multidrug-resistant bacteria. The initial focus will be on treating chronic infections associated with cystic...
21:05 , Jun 21, 2018 |  BC Extra  |  Company News

UCSD launches bacteriophage treatment center

The University of California San Diego launched the Center for Innovative Phage Applications and Therapeutics (IPATH) to develop bacteriophages to fight multidrug-resistant bacteria. The initial focus will be on treating chronic infections associated with cystic...
11:00 , Jun 6, 2018 |  BC Extra  |  Politics & Policy

ARM Foundation for Cell and Gene Medicine launched

The Alliance for Regenerative Medicine (ARM) launched an independent, non-profit foundation dedicated to researching, creating and disseminating information about gene and cell therapies. The ARM Foundation for Cell and Gene Medicine has commissioned a study...
00:51 , Feb 9, 2018 |  BC Innovations  |  Product R&D

Debugging the microbiome

BiomX Ltd. is moving phage therapies beyond infectious disease and into chronic conditions driven by the microbiome. The Israeli biotech has pieced together a suite of tools that can identify bad actors within microbial communities...
18:11 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

AmpliPhi reports data from expanded access program for bacteriophages

AmpliPhi Biosciences Corp. (NYSE-M:APHB) reported data from seven patients with serious, life-threatening infections who did not respond to antibiotics from an expanded access program showing that AB-SA01 or AB-PA01 (Biophage-PR, AmpliPhage-001) in combination with best...
17:34 , Aug 31, 2017 |  BC Innovations  |  Product R&D

Cutting through resistance

Most companies employing CRISPR- Cas9 for therapeutics are using it to edit human cells, but Locus Biosciences Inc. is betting the lesser-known CRISPR- Cas3 system will do a better job of treating bacterial infections and...
19:50 , Aug 3, 2017 |  BC Innovations  |  Strategy

FDA's phage philosophy

Against a backdrop of doubt about the regulators’ outlook for bacteriophage therapeutics, FDA is assuring drug developers the re-emerging modality is firmly on the table. The position should assuage at least some concerns in a...
22:43 , Jul 7, 2017 |  BioCentury  |  Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the...
00:30 , Jun 9, 2017 |  BC Extra  |  Company News

Management tracks

Neurological diseases play Flex Pharma Inc. (NASDAQ:FLKS) said Christoph Westphal will step down as CEO, effective July 3. He will remain chairman. President of R&D William McVicar will be interim CEO. Cancer company ViraTherapeutics GmbH...